WILMINGTON – Incyte secured on Monday the first U.S. Food & Drug Administration approval for a treatment of the skin pigmentation disorder vitiligo, demonstrating the growing strength of the biopharmaceutical […]
WILMINGTON – Pharmaceutical giant AstraZeneca has acquired Caelum Biosciences, a small clinical-stage biotechnology company, for $150 million. The New Jersey-based Caelum was founded by New York-based biopharma company Fortress Biotech […]
WILMINGTON – Biopharmaceutical giant Incyte Corp. announced Monday that it has bought into a new collaboration deal on a monoclonal antibody, paying about $152 million to Massachusetts-based clinical stage company […]
Organic light-emitting diode (OLED) screens. Intraocular lenses. Emerging medicines and much, much more. New Castle-based Adesis specializes in producing difficult-to-make chemicals, which allows companies around the world to create new […]
WILMINGTON – The U. S Food and Drug Administration has granted approval to Lynparza, AstraZeneca and Merck’s PARP inhibitor for maintenance therapy for some ovarian cancer patients, according to the […]
The Food and Drug Administration has granted breakthrough therapy designation for ruxolitinib — Incyte Corporation’s treatment for patients with acute graft-versus-host disease. The drug, trademarked Jakafi, is the first approved […]
By Christi Milligan The University of Delaware Cooperative Extension has incorporated the impact of FSMA into their workshops and educational materials. David Marvel Jr. just finished planting nearly a quarter of […]
Premier Digital Partners
© 2024 Delaware Business Times
